iCAD (NASDAQ:ICAD) Raised to Hold at StockNews.com

iCAD (NASDAQ:ICAD) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday.

iCAD Stock Performance

Shares of NASDAQ ICAD opened at $2.70 on Thursday. The business’s 50-day simple moving average is $2.46 and its 200-day simple moving average is $1.93. iCAD has a 52 week low of $1.18 and a 52 week high of $3.78. The firm has a market cap of $71.66 million, a price-to-earnings ratio of -20.77 and a beta of 1.47.

Institutional Trading of iCAD

Several large investors have recently modified their holdings of ICAD. waypoint wealth counsel raised its holdings in iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares during the period. Thompson Davis & CO. Inc. bought a new position in shares of iCAD in the fourth quarter worth about $31,000. PKS Advisory Services LLC acquired a new position in shares of iCAD during the 4th quarter worth about $53,000. Wells Fargo & Company MN boosted its stake in iCAD by 51.3% during the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after purchasing an additional 13,402 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new stake in iCAD in the 4th quarter valued at approximately $92,000. 24.61% of the stock is owned by institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.